Abstract C61: Non-homogeneous drug penetrance of veliparib measured in triple negative breast tumors
Imke H. Bartelink(University of California, San Francisco), Laura van'tVeer(University of California, San Francisco), Byron Hann(University of California, San Francisco), Diane Heditsian(University of California, San Francisco), Lisa J. Wilmes(University of California, San Francisco), Pei R.E. Lee(University of California, San Francisco), Douglas Yee(University of Minnesota Medical Center), Ella F. Jones(University of California, San Francisco), Jean‐Philippe Coppé(University of California, San Francisco), Lamorna Swigart-Brown(UCSF Helen Diller Family Comprehensive Cancer Center), Ron J. Keizer(Slotervaartziekenhuis), Brendan Prideaux(Hackensack Meridian Health), Sergey Magnitsky(University of California, San Francisco), Laura J. Esserman(University of California, San Francisco), Alan H.B. Wu(University of California, San Francisco), Gregor Krings(Cleveland Clinic), Weiming Ruan(University of California, San Francisco), Denise M. Wolf, Rada Savic(University of California, San Francisco), Véronique Dartois(Hackensack Meridian Health)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
|Unknown|2008|4.1k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k